Enliven Therapeutics Stock Last Dividend Paid
| ELVN Stock | 21.08 0.16 0.76% |
Enliven Therapeutics fundamentals help investors to digest information that contributes to Enliven Therapeutics' financial success or failures. It also enables traders to predict the movement of Enliven Stock. The fundamental analysis module provides a way to measure Enliven Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Enliven Therapeutics stock.
Enliven | Last Dividend Paid |
Enliven Therapeutics Company Last Dividend Paid Analysis
Enliven Therapeutics' Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
More About Last Dividend Paid | All Equity Analysis
Last Dividend | = | Last Profit Distribution AmountTotal Shares |
Enliven Last Dividend Paid Driver Correlations
Understanding the fundamental principles of building solid financial models for Enliven Therapeutics is extremely important. It helps to project a fair market value of Enliven Stock properly, considering its historical fundamentals such as Last Dividend Paid. Since Enliven Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Enliven Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Enliven Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.
| Competition |
Enliven Dividend Paid And Capex Coverage Ratio
Dividend Paid And Capex Coverage Ratio |
|
Based on the recorded statements, Enliven Therapeutics has a Last Dividend Paid of 0.0. This indicator is about the same for the Pharmaceuticals average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Investing Opportunities Now
Investing OpportunitiesBuild portfolios using our predefined set of ideas and optimize them against your investing preferences |
| All Next | Launch Module |
Enliven Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Enliven Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Enliven Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Enliven Fundamentals
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.22 | ||||
| Current Valuation | 731.95 M | ||||
| Shares Outstanding | 49 M | ||||
| Shares Owned By Insiders | 6.42 % | ||||
| Shares Owned By Institutions | 93.58 % | ||||
| Number Of Shares Shorted | 7.44 M | ||||
| Price To Book | 3.30 X | ||||
| EBITDA | (104.55 M) | ||||
| Net Income | (89.02 M) | ||||
| Total Debt | 15.91 M | ||||
| Book Value Per Share | 6.33 X | ||||
| Cash Flow From Operations | (73.19 M) | ||||
| Short Ratio | 36.97 X | ||||
| Earnings Per Share | (1.89) X | ||||
| Target Price | 37.86 | ||||
| Number Of Employees | 62 | ||||
| Beta | 1.15 | ||||
| Market Capitalization | 1.03 B | ||||
| Total Asset | 325.76 M | ||||
| Retained Earnings | (243.47 M) | ||||
| Working Capital | 302.21 M | ||||
| Net Asset | 325.76 M |
About Enliven Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Enliven Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Enliven Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Enliven Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether Enliven Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enliven Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enliven Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enliven Therapeutics Stock: Check out Enliven Therapeutics Piotroski F Score and Enliven Therapeutics Altman Z Score analysis. To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enliven Therapeutics. If investors know Enliven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enliven Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Enliven Therapeutics is measured differently than its book value, which is the value of Enliven that is recorded on the company's balance sheet. Investors also form their own opinion of Enliven Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enliven Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enliven Therapeutics' market value can be influenced by many factors that don't directly affect Enliven Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enliven Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enliven Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enliven Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.